Nilotinib (AMN-107)

Catalog No.S1033

Nilotinib (AMN-107) Chemical Structure

Molecular Weight(MW): 529.52

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 210 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
Features A selective inhibitor of native and mutant Bcr-Abl.
Targets
Bcr-Abl [1]
(Murine myeloid progenitor cells)
<30 nM
In vitro

Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DjNmlEPTB;MD6wNFAyPDRizszN Mlu4V2FPT0WU
KU812 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjmenhEUUN3ME2wMlAxOjR6IN88US=> MXLTRW5ITVJ?
EM-2 NIrRfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnzVGNyUUN3ME2wMlAxPDFizszN MYjTRW5ITVJ?
LAMA-84 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfle3NKSzVyPUCuNFA1QSEQvF2= MoPLV2FPT0WU
MEG-01 NXjUSpRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7vcmNbUUN3ME2wMlAxQDJ6IN88US=> NUHUWVg4W0GQR1XS
BV-173 NVHVUG56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEGwPFkh|ryP NEfHRXRUSU6JRWK=
KASUMI-1 NXvRWHM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonlTWM2OD1yLkCyOFE{KM7:TR?= NHfsNG9USU6JRWK=
NB7 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMUO0N|kh|ryP NEXXdItUSU6JRWK=
BHT-101 MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwNkSyOlMh|ryP NYTHcGM5W0GQR1XS
CGTH-W-1 M2LuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHmRmdKSzVyPUCuOlQ5PyEQvF2= NYHBT|NGW0GQR1XS
HMV-II M1jCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULSUYJQUUN3ME2wMlc1QDd2IN88US=> MXrTRW5ITVJ?
NKM-1 NXfEXoZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q0cGlEPTB;MD65NFE2KM7:TR?= M3yzVHNCVkeHUh?=
LB2241-RCC Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFwMEKyNlgh|ryP M4XjXXNCVkeHUh?=
NCI-H1703 NGTCdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjRN41KSzVyPUGuNVg5PyEQvF2= NEDSToFUSU6JRWK=
BE-13 MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDCTWM2OD1zLkK3OFE3KM7:TR?= Ml7VV2FPT0WU
ACN NH\CfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPpbodoUUN3ME2xMlU2ODd5IN88US=> MmH0V2FPT0WU
A204 NFX1U|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPLTGFKSzVyPUGuOVczODVizszN NELQUVhUSU6JRWK=
HOP-62 M1PGS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTaTWM2OD1zLkiyNFc4KM7:TR?= NFvYXJNUSU6JRWK=
H9 NESxXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;0SYRKSzVyPUKuO|M4QTNizszN MX3TRW5ITVJ?
HCC1806 NV3tO|dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HOb2lEPTB;Mj63OFMzPyEQvF2= MXXTRW5ITVJ?
NOS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP3Z5JHUUN3ME2yMlg4OTB{IN88US=> NYjDeWZXW0GQR1XS
RS4-11 M4rSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HZZmlEPTB;Mj65NFYzOyEQvF2= NWjWPWpiW0GQR1XS
JAR NELXOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe2NXhKSzVyPUKuPVIxQDRizszN NFHDUVRUSU6JRWK=
T98G M4H6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NECwb5ZKSzVyPUOuNFE{OTNizszN NHW1b|BUSU6JRWK=
NCI-SNU-1 NXjzT2NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTNwNECwPVIh|ryP NXHT[ld4W0GQR1XS
SK-MEL-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm3RYhKSzVyPUOuOFMxOjlizszN NXjmdXpEW0GQR1XS
L-363 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XJcGlEPTB;Mz62NVExPyEQvF2= MYnTRW5ITVJ?
SW982 NICxWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjUc4pKSzVyPUOuOlQyPjlizszN M2nRfnNCVkeHUh?=
HT-1080 M3SyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrJTWM2OD1|LkmxO|c2KM7:TR?= M4jJ[3NCVkeHUh?=
G-402 NILve4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTLOVlKUUN3ME20MlMyOjB|IN88US=> NGLyZpRUSU6JRWK=
HOS NV2yNnFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHoTWM2OD12LkiwNlgzKM7:TR?= Mmq2V2FPT0WU
SK-NEP-1 M2DXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjvSVBtUUN3ME20Mlg{OTlzIN88US=> NGnB[JBUSU6JRWK=
HAL-01 M3iybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrHUmhKSzVyPUSuPFgzPDJizszN MYXTRW5ITVJ?
SBC-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjLSYNKSzVyPUSuPVA6ODdizszN Mlj5V2FPT0WU
CTV-1 M{e4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDSdYs{UUN3ME21MlQ5QTN6IN88US=> NEjIRopUSU6JRWK=
LCLC-103H NEK0ZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC5d4FKSzVyPUWuO|c1PzFizszN NXu0em1WW0GQR1XS
RVH-421 M4nITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLabmRKSzVyPUWuO|c2OzZizszN NX3hWlBDW0GQR1XS
K-562 NUDUfolkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPhPIRUUUN3ME21MlkxOzZizszN MnfmV2FPT0WU
CAL-33 NWnqOYNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\rTWM2OD14LkOxN|U6KM7:TR?= MXHTRW5ITVJ?
MDA-MB-361 M1K1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXKSWVXUUN3ME22MlM{Pjl7IN88US=> NGf1ZW5USU6JRWK=
IGROV-1 NWXBdY9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn4NYRrUUN3ME22MlQ4OTlzIN88US=> NIjSNZhUSU6JRWK=
NY NHzPZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3STWM2OD14LkWzOVk6KM7:TR?= NYnGZpQxW0GQR1XS
Ramos-2G6-4C10 M3fhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzvTWM2OD14Lk[2PVMyKM7:TR?= MnPiV2FPT0WU
HuO9 NGDXUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTZwN{O5OlQh|ryP NIHIW|RUSU6JRWK=
MS-1 NYjCW3RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLrTWM2OD15LkGxPVU{KM7:TR?= MWPTRW5ITVJ?
RPMI-8226 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTdwMkiyPFch|ryP NFLpTXhUSU6JRWK=
HDLM-2 M3LZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDHTWM2OD15LkSwNVQ6KM7:TR?= MWrTRW5ITVJ?
D-566MG MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP6TWM2OD15LkS3NVU2KM7:TR?= Mle0V2FPT0WU
SK-MEL-24 M1\TeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M376RWlEPTB;Nz62N|M6OiEQvF2= M4i3bnNCVkeHUh?=
COLO-679 NEO3VZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHPVWxRUUN3ME23Mlk5PjdzIN88US=> MUXTRW5ITVJ?
EW-13 M4XkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRThwM{KwOVQh|ryP MVrTRW5ITVJ?
A388 NXTZ[IFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRThwM{i0PFEh|ryP NUnteWJYW0GQR1XS
UM-UC-3 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3MZ4N[UUN3ME24MlQ{QTV4IN88US=> MYTTRW5ITVJ?
NUGC-3 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uxRWlEPTB;OD61N|U5OiEQvF2= MnrDV2FPT0WU
COLO-668 NVvhSYFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnSTWM2OD16LkW5OFkyKM7:TR?= NHj6TFhUSU6JRWK=
MOLT-4 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnYVo1KSzVyPUiuOlI{PTNizszN MV7TRW5ITVJ?
D-423MG MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\3UYpjUUN3ME24Mlg{PzV4IN88US=> M{LzPHNCVkeHUh?=
CTB-1 M1Xic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy2b3lKSzVyPUiuPFcyOjhizszN M2TlV3NCVkeHUh?=
BCPAP M321e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTlwMEK1OlIh|ryP MkT1V2FPT0WU
GCT MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDZTHY4UUN3ME25MlA6QDNzIN88US=> MnrVV2FPT0WU
ACHN NHHsd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTlwMkO2N|Ih|ryP NX\iRXY{W0GQR1XS
KYSE-520 MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm3e3VbUUN3ME25MlM{PDh{IN88US=> NWPlSJpIW0GQR1XS
LB771-HNC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu1ZoRyUUN3ME25Mlc3PDl5IN88US=> M1HWbnNCVkeHUh?=
MLMA NETjfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PBdmlEPTB;MUCuNFE{OiEQvF2= MXnTRW5ITVJ?
HEC-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvJTWM2OD1zMD6yPFA1KM7:TR?= MVPTRW5ITVJ?
HL-60 NEnjVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKzUnVKSzVyPUGwMlY5PTNizszN MX3TRW5ITVJ?
A101D MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uyTWlEPTB;MUCuPFkzOyEQvF2= NHq0[XFUSU6JRWK=
A2058 M4Cxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYCwe|Z2UUN3ME2xNE46OjR3IN88US=> MmS1V2FPT0WU
KARPAS-45 M2XaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFzLkC2N|Uh|ryP Ml7iV2FPT0WU
697 NVm4cI15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFzLkKxNFEh|ryP MUnTRW5ITVJ?
NCI-N87 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFzLke3N|Eh|ryP MX7TRW5ITVJ?
DSH1 MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H3TmlEPTB;MUGuO|k2OyEQvF2= M4jhfnNCVkeHUh?=
HLE MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\DT2lEPTB;MUGuPFg{QSEQvF2= NUHFZ|hRW0GQR1XS
NCI-H720 Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H6UWlEPTB;MUKuOlgxOSEQvF2= MljyV2FPT0WU
EW-3 NH7qV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HufGlEPTB;MUKuPVMxPyEQvF2= M4L0RXNCVkeHUh?=
AGS NF\nN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnuSYhKSzVyPUGzMlA{PTFizszN M37iUnNCVkeHUh?=
ES5 M4XvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnToTWM2OD1zMz6wOVEzKM7:TR?= MYjTRW5ITVJ?
DB NW\6R5V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnftTWM2OD1zMz6zNlU3KM7:TR?= MYjTRW5ITVJ?
A4-Fuk MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf6TWM2OD1zMz60NVAzKM7:TR?= MmLRV2FPT0WU
A427 NEm0c2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XXSWlEPTB;MUOuOFk4OiEQvF2= NFnaU5RUSU6JRWK=
MN-60 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLQTWM2OD1zMz61PFQ{KM7:TR?= NYfyR|lNW0GQR1XS
HCC2218 NITrV|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPtO5RIUUN3ME2xN{42QDV4IN88US=> MVHTRW5ITVJ?
MV-4-11 NXjBPWViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTyVo5CUUN3ME2xN{45OTN5IN88US=> MkWzV2FPT0WU
GI-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS5T2pKSzVyPUG0MlEyQDRizszN MUHTRW5ITVJ?
JVM-3 NGDhVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C3OWlEPTB;MUSuNlY2PiEQvF2= NGXzNYNUSU6JRWK=
NCI-H2029 NXrvU5N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LPOmlEPTB;MUSuNlczPyEQvF2= M1TQc3NCVkeHUh?=
TE-12 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrxNFI6UUN3ME2xOE43ODR4IN88US=> MlTIV2FPT0WU
WM-115 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO5TWM2OD1zNT61Olg{KM7:TR?= Mn20V2FPT0WU
BB65-RCC NWLCd2pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XVbGlEPTB;MU[uNFI1OSEQvF2= M3P6enNCVkeHUh?=
NCI-H1693 NIS4RYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF4LkO4NFIh|ryP NGLadZhUSU6JRWK=
KARPAS-299 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH0TWM2OD1zNj62NlA{KM7:TR?= Ml;HV2FPT0WU
UACC-257 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzBb5dQUUN3ME2xO{4xPTh{IN88US=> NXLlPIlUW0GQR1XS
RKO M3rEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTnUmtKSzVyPUG3MlY1OzNizszN MnPSV2FPT0WU
HT-29 NIHVbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrEe3JJUUN3ME2xO{44QDh7IN88US=> NEjxenZUSU6JRWK=
ES7 NF65dIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TUNWlEPTB;MUiuNVEzOiEQvF2= NV71WmIyW0GQR1XS
DEL NELqS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLOTWM2OD1zOD6zNVczKM7:TR?= NHnNS4xUSU6JRWK=
BT-549 MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e4UGlEPTB;MUiuOFA6OiEQvF2= NVy3eoJKW0GQR1XS
NCI-H1755 M4XOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HzUmlEPTB;MUiuOVczOyEQvF2= MXvTRW5ITVJ?
HCE-T NVy2V4dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGCwRXNKSzVyPUG4Mlg{PDFizszN MUTTRW5ITVJ?
LU-139 NXfWXHZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M174d2lEPTB;MUmuNFQ2QCEQvF2= M1rE[nNCVkeHUh?=
ECC10 NUP2R5pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\vcIp4UUN3ME2xPU4zPDd3IN88US=> MYLTRW5ITVJ?
769-P NUK1UoZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjvO3FKSzVyPUG5MlY{OzVizszN MkjSV2FPT0WU
BALL-1 MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF7Lk[3O|Uh|ryP NVPSRWo1W0GQR1XS
LXF-289 NH7p[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfXTWM2OD1zOT64PVc6KM7:TR?= MWXTRW5ITVJ?
TYK-nu NFrueHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfGVYxKSzVyPUG5Mlk{OTVizszN MoXTV2FPT0WU
NCI-H630 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfSSJZKSzVyPUG5Mlk{PzhizszN MULTRW5ITVJ?
EW-18 NI\CVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTqSWdKSzVyPUKwMlM5ODJizszN M3K5[nNCVkeHUh?=
KYSE-150 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX3eIZKSzVyPUKwMlcxPDdizszN NH60dWVUSU6JRWK=
LOXIMVI NH\xO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16wN2lEPTB;MkCuO|U5PiEQvF2= MlHWV2FPT0WU
HuP-T3 M4\BSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJzLkC4OVIh|ryP Mn62V2FPT0WU
MFE-280 M13wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJzLkW2O|kh|ryP NX:4N2VPW0GQR1XS
SK-OV-3 NYjGW5FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;USJJIUUN3ME2yNU45PDB6IN88US=> NHu0PJFUSU6JRWK=
QIMR-WIL NWPX[mtLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HiO2lEPTB;MkKuNFQ4QCEQvF2= M2HVeHNCVkeHUh?=
NCI-H69 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:2epFGUUN3ME2yNk41Ojl7IN88US=> NH[wXlhUSU6JRWK=
TE-5 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jWVGlEPTB;MkKuOFk3PSEQvF2= NIntbnNUSU6JRWK=
NCI-H1993 NUDwTYdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULqWHhiUUN3ME2yNk41QTdzIN88US=> MYLTRW5ITVJ?
NCI-H1092 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPZTWM2OD1{Mz6yPFQ{KM7:TR?= NI\VS5BUSU6JRWK=
RH-1 NEWxbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHFTnRKSzVyPUKzMlU{PTdizszN M2DKXnNCVkeHUh?=
DBTRG-05MG M{Xqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLZRpBKSzVyPUKzMlg1PzJizszN MlHkV2FPT0WU
Mo-T NEHme|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPaTWM2OD1{Mz65JO69VQ>? M13uO3NCVkeHUh?=
HD-MY-Z MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP4TWM2OD1{ND6yN|YzKM7:TR?= MnzlV2FPT0WU
NCI-H2342 NUDNW3JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjxRYJPUUN3ME2yOE43PzZ5IN88US=> MWfTRW5ITVJ?
C32 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3qzWWlEPTB;MkSuPVU4PiEQvF2= NHXCT|NUSU6JRWK=
HTC-C3 NYjx[HdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJ3LkO1O|ch|ryP NGnMOoZUSU6JRWK=
NCI-H358 MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJ3LkO5OFMh|ryP NFLpb|NUSU6JRWK=
CAL-85-1 M{nRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\FbW1KSzVyPUK1MlQ2PzdizszN MWDTRW5ITVJ?
HT-1197 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ3LkWzNVkh|ryP NGfsUZBUSU6JRWK=
A172 MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PsRWlEPTB;MkWuO|E{PiEQvF2= NELqc|VUSU6JRWK=
SW1573 NHPQd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL1RWpKSzVyPUK1Mlc4QDVizszN M4PURXNCVkeHUh?=
EW-24 NEHkWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ3Lkm2NkDPxE1? NXzWRop[W0GQR1XS
SK-MEL-2 M1vQZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK5TWM2OD1{Nj6wN|EzKM7:TR?= MoX3V2FPT0WU
LU-65 M1W4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPNTWM2OD1{Nj6wOFUzKM7:TR?= NIPHV2NUSU6JRWK=
KMOE-2 NU\SXZN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDJPVhKSzVyPUK2MlA6OTVizszN M{\sbXNCVkeHUh?=
H-EMC-SS MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v5ZmlEPTB;Mk[uOFEyPCEQvF2= NEXQTWNUSU6JRWK=
H4 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn3TWM2OD1{Nj60NlQ{KM7:TR?= MnzLV2FPT0WU
DU-4475 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK3TWM2OD1{Nz6xPFczKM7:TR?= NHXNSWpUSU6JRWK=
HCT-116 MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXThd5dbUUN3ME2yO{41OzR7IN88US=> MY\TRW5ITVJ?
MSTO-211H NGCzfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjnN25KSzVyPUK3MlYzPTVizszN M17SbnNCVkeHUh?=
NCI-H292 NWXPRWtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ5Lkm2NVch|ryP NXfmS29LW0GQR1XS
NCI-H446 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\kWnAzUUN3ME2yPE4zOTB3IN88US=> MX3TRW5ITVJ?
NCI-H2009 M1TP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXK[m51UUN3ME2yPU4yPDNzIN88US=> Mo\TV2FPT0WU
MHH-ES-1 NXXybZFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i3OmlEPTB;MkmuN|Y5PSEQvF2= MmDKV2FPT0WU
TI-73 MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHHcYZKSzVyPUK5MlQxODFizszN NIHsNYFUSU6JRWK=
NCI-H2228 MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSwTWM2OD1{OT60OVgh|ryP MkL5V2FPT0WU
MHH-PREB-1 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnQOm9WUUN3ME2yPU42PTB3IN88US=> MUDTRW5ITVJ?
ChaGo-K-1 M4LsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfLXY9PUUN3ME2yPU43ODl5IN88US=> MYDTRW5ITVJ?
KY821 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\WdWlEPTB;MkmuOlQ{OyEQvF2= NYTOT3hmW0GQR1XS
NCI-H209 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnFW4JJUUN3ME2yPU45OzZ4IN88US=> NHjtPI1USU6JRWK=
NBsusSR NHHTdotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly5TWM2OD1{OT65PVA1KM7:TR?= NVnCPJVRW0GQR1XS
NCI-H1304 NYPmU5lET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPRV4xkUUN3ME2zNE42PzF4IN88US=> M174VHNCVkeHUh?=
NB14 NVTtN3F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O2[GlEPTB;M{GuNFQ1PiEQvF2= M2\VUnNCVkeHUh?=
HCC1419 NVq1WZFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfqNFhKSzVyPUOxMlI1KM7:TR?= M13jNXNCVkeHUh?=
KG-1 NUH1[|ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO1OJdtUUN3ME2zNU44PDJ7IN88US=> NX3od5gzW0GQR1XS
A2780 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHPU5hKSzVyPUOxMlg{PThizszN NFr0TYtUSU6JRWK=
NCI-H28 M1jtcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPhO2xKSzVyPUOxMlk5PjFizszN NYr6c2pNW0GQR1XS
C2BBe1 NVTHZ3lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImzWpBKSzVyPUOyMlI3OzRizszN NV21ZpBJW0GQR1XS
VA-ES-BJ NVfTOVloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPKTWM2OD1|Mj6zNUDPxE1? NIHCPHFUSU6JRWK=
SBC-5 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL3[2xKSzVyPUOyMlg2OTFizszN M3\RWnNCVkeHUh?=
OVCAR-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4SyV2lEPTB;M{OuOFg1QCEQvF2= MnXyV2FPT0WU
COR-L88 Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTN2LkC3OFEh|ryP NXf1TYlsW0GQR1XS
SW954 NF7rT5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTN2LkC3OVIh|ryP Mlu0V2FPT0WU
COLO-684 M3mxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XsbWlEPTB;M{SuN|QxPCEQvF2= NHPKUnFUSU6JRWK=
HCC70 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTN2Lkm1NVQh|ryP NYrCbmNIW0GQR1XS
NCI-H1770 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGyRXNoUUN3ME2zOE46PjFizszN MULTRW5ITVJ?
NCI-H1666 M3fzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTN3LkiyOVMh|ryP M3H6VXNCVkeHUh?=
YH-13 NFjwNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq3eGJKSzVyPUO1MlkzKM7:TR?= Mkf6V2FPT0WU
DJM-1 NG\idYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrqTWM2OD1|Nj64NFQ6KM7:TR?= NIC4THhUSU6JRWK=
KNS-62 Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPqTWM2OD1|Nj65OFM5KM7:TR?= M1GwW3NCVkeHUh?=
SK-MEL-30 NFXtdYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r2NmlEPTB;M{euPFc{PyEQvF2= MWDTRW5ITVJ?
SJRH30 Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfCdnVKSzVyPUO4Mlc{PDFizszN M4j2VnNCVkeHUh?=
GP5d MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i3R2lEPTB;M{iuPFY2OyEQvF2= NGe2fW5USU6JRWK=
SW1116 NV\uS|VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLSNZR6UUN3ME2zPU4zQDB3IN88US=> MoXMV2FPT0WU
COLO-800 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoCwTWM2OD1|OT6zOlM5KM7:TR?= MojOV2FPT0WU
RD MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTN7LkWyOVgh|ryP M1e2ZXNCVkeHUh?=
NCI-SNU-5 MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vONmlEPTB;M{muOlkyPiEQvF2= MlLkV2FPT0WU
HuO-3N1 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M120emlEPTB;NECuNVA5KM7:TR?= NHPDSYtUSU6JRWK=
SK-UT-1 NGW4dldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTRyLkW2O|Qh|ryP MU\TRW5ITVJ?
SK-MEL-3 NGWxb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTRyLkW5N|Ih|ryP MnjjV2FPT0WU
SK-MEL-28 M1qyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXxTWM2OD12MD62OFM2KM7:TR?= NGXscXVUSU6JRWK=
SCC-4 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\Dc4dKSzVyPUSxMlIyOzdizszN NVz6fGxNW0GQR1XS
no-11 M{K3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrPfHJ1UUN3ME20NU44OzV2IN88US=> MUHTRW5ITVJ?
HT-144 NYPT[5JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXQUIs5UUN3ME20Nk4xPTZ5IN88US=> M1vaRnNCVkeHUh?=
MFM-223 NYXGOHVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTR{LkSwNkDPxE1? MVHTRW5ITVJ?
ONS-76 NHzybHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;sVmdKSzVyPUSyMlgxOThizszN MX3TRW5ITVJ?
ES8 M4jzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPjfYdKSzVyPUSzMlM3QThizszN MUPTRW5ITVJ?
T-24 M{fGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTR|LkSzOlkh|ryP NFu1XWxUSU6JRWK=
GAMG NWfPbZg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTR|LkS1NVch|ryP M1nIdHNCVkeHUh?=
LU-135 M4rFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWydItQUUN3ME20OE4xQTJ|IN88US=> M4X1VXNCVkeHUh?=
HCC1187 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnHOZA5UUN3ME20OE45OjZ{IN88US=> MoHLV2FPT0WU
TE-1 NUTC[ZZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzvTWM2OD12NT6xOlU1KM7:TR?= M3r6[nNCVkeHUh?=
J-RT3-T3-5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7repk3UUN3ME20OU41OzF3IN88US=> NWDSXGFiW0GQR1XS
GI-ME-N MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi2O45kUUN3ME20OU45QTV{IN88US=> M1j4dHNCVkeHUh?=
D-392MG M2X5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTwTWM2OD12NT65NlU3KM7:TR?= MWfTRW5ITVJ?
KALS-1 NGjnV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrETWM2OD12Nj63NlU4KM7:TR?= NGr4cJVUSU6JRWK=
MMAC-SF M2jIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDzTWM2OD12Nj65PVUzKM7:TR?= MX;TRW5ITVJ?
HSC-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X5SGlEPTB;NEeuN|YxQCEQvF2= MULTRW5ITVJ?
KM-H2 MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTR5Lk[wNFch|ryP MYHTRW5ITVJ?
LoVo NHLROZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq1bGVoUUN3ME20PE4yODB{IN88US=> Mnv3V2FPT0WU
NCI-H510A Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:y[oFKSzVyPUS4MlE5PzFizszN NVjQZY5kW0GQR1XS
EW-11 NEW4PWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;WTWM2OD12OD6yN|Q5KM7:TR?= Mm[3V2FPT0WU
HCC2998 M330W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITYSWpKSzVyPUS4MlYzOzZizszN NV\WS3c2W0GQR1XS
J82 MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TYNmlEPTB;NEiuO|I1OiEQvF2= M1;pcHNCVkeHUh?=
ML-2 NH3ae4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n6c2lEPTB;NEmuOFYxPSEQvF2= NFew[VJUSU6JRWK=
NCI-H2030 M1;2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG0TWM2OD12OT63NVE4KM7:TR?= NGm3WINUSU6JRWK=
NCI-H1792 M{LjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojoTWM2OD12OT64OVE5KM7:TR?= NYPXdG5iW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AMPKα / AMPKα / p-AMPKβ1 / AMPKγ2 / p-LKB1 / LKB1 / CaMKIIβ ; 

PubMed: 23677989     


Dose-dependent analysis of AMPK-related molecules in HCC cells. Cells were exposed to nilotinib at the indicated concentrations for 24 h.

DNMT1 / DNMT3a / DNMT3b ; 

PubMed: 28720666     


Kasumi-1 or MV4-11 cells were treated for 24 h with the indicated doses of nilotinib and subjected western blot analysis to detect the expression levels of DNMT1, DNMT3a, DNMT3b.

pABL1 / p-NF-κB1 / NF-κB / STAT3 / p-STAT3 / IL-1β / IL-6 / COX2 ; 

PubMed: 31396300     


ABL1 regulated the inflammation signaling pathway. Blocking activities of ABL1 with Imatinib and Nilotinib inhibits the inflammatory signaling pathway including activities of NF-κB1, STAT3, IL-1β, IL-6, and COX2.

23677989 28720666 31396300
Growth inhibition assay
Cell viability; 

PubMed: 23677989     


Dose-dependent effects of nilotinib on cell viability. HCC cells were treated with nilotinib at the indicated concentrations for 72 h. Cell viability was measured by MTT assay. Points, mean; bars, S.D. (n = 8). 

23677989
In vivo Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: Human primary Schwann and schwannoma cells
  • Concentrations: 1-10 μM
  • Incubation Time: 72 hours
  • Method: Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
  • Formulation: 10% NMP-90% PEG300, PEG300
  • Dosages: 75 mg/kg, 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (50.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 529.52
Formula

C28H22F3N7O

CAS No. 641571-10-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04002674 Recruiting Drug: Placebo oral capsule|Drug: Nilotinib Oral Capsule Dementia With Lewy Bodies Georgetown University|National Institutes of Health (NIH) November 2019 Phase 2
NCT03942094 Not yet recruiting Drug: Nilotinib Chronic Myeloid Leukemia Chronic Phase|Nilotinib Shenzhen Second People''s Hospital June 1 2019 Phase 3
NCT03874858 Recruiting Drug: Nilotinib Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis March 22 2019 Phase 2
NCT02973711 Suspended Drug: Nilotinib|Drug: Ruxolitinib Leukemia Chronic Myeloid University of Michigan Rogel Cancer Center January 18 2018 Phase 1|Phase 2
NCT03228303 Not yet recruiting Drug: Nilotinib 150 MG [Tasigna]|Drug: Imatinib 400mg Chronic Myeloid Leukemia Assiut University December 1 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use AMN-107 for in vivo studies in mice, can you give me some suggestions about the in vivo formulation?

  • Answer:

    For in vivo study, we recommend to use 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 3mg/ml.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products

Tags: buy Nilotinib (AMN-107) | Nilotinib (AMN-107) supplier | purchase Nilotinib (AMN-107) | Nilotinib (AMN-107) cost | Nilotinib (AMN-107) manufacturer | order Nilotinib (AMN-107) | Nilotinib (AMN-107) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID